Revumenib

Product Description

Revumenib is an orally bioavailable protein-protein interaction (PPI) inhibitor of the menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) proteins, with potential antineoplastic activity. Upon oral administration, revumenib targets and binds to the nuclear protein menin, thereby preventing the interaction between the two proteins menin and MLL and the formation of the menin-MLL complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of MLL-rearranged leukemic cells. The menin-MLL complex plays a key role in the survival, growth, transformation and proliferation of certain kinds of leukemia cells. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Revumenib)

Mechanisms of Action: MEN1 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation:
Breakthrough Therapy - Acute Leukemia|Leukemia
Fast Track - Acute Leukemia|Leukemia
Orphan Drug - Acute Leukemia|Acute Myeloid Leukemia|Leukemia|Myeloid Leukemia *

Approval Status: Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Syndax
Company Location: WALTHAM MA 02451
Company CEO: Michael A. Metzger
Additonal Commercial Interests: None